Celldex (CLDX) SVP granted 95,000 options at $34.09 strike

Rhea-AI Filing Summary

Celldex Therapeutics, Inc. reported that SVP of Regulatory Affairs Margo Heath-Chiozzi received an incentive stock option grant. The award covers 95,000 options to buy Celldex common stock at an exercise price of $34.09 per share, with 95,000 options held after the transaction.

According to the footnotes, the grant was made under the company’s 2021 Omnibus Equity Incentive Plan. Twenty-five percent of the options vest on June 25, 2027, and the remaining options vest in equal quarterly installments over the following 12 quarters, with the options expiring on June 25, 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Heath-Chiozzi Margo

Role SVP OF REGULATORY AFFAIRS

Type	Security	Shares	Price	Value
Grant/Award	Incentive Stock Option (right to buy)	95,000	$0.00	--

Holdings After Transaction: Incentive Stock Option (right to buy) — 95,000 shares (Direct, null)

Footnotes (1)

1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

Key Figures

Option grant size: 95,000 options Exercise price: $34.09 per share Underlying shares: 95,000 shares +4 more

7 metrics

Option grant size 95,000 options Incentive Stock Option grant to SVP of Regulatory Affairs

Exercise price $34.09 per share Strike price for Incentive Stock Option grant

Underlying shares 95,000 shares Common stock underlying the options

Options after transaction 95,000 options Total options held following the grant

Initial vesting date June 25, 2027 25% of options vest on this date

Vesting schedule remainder 12 quarterly installments Remaining 75% vest over subsequent quarters

Option expiration June 25, 2036 Expiration date of the incentive stock options

Key Terms

Incentive Stock Option, 2021 Omnibus Equity Incentive Plan, vest, underlying security

4 terms

Incentive Stock Option financial

"Incentive Stock Option (right to buy)"

An incentive stock option is a type of employee benefit that gives a worker the right to buy company shares at a fixed price, with special tax advantages if the employee holds the shares for a required period. Think of it as a coupon to buy future shares at today’s price that can result in lower tax on the gain. Investors care because ISOs can dilute share count, align staff incentives with the stock price, and affect company compensation costs and the timing of potential share sales.

2021 Omnibus Equity Incentive Plan financial

"granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan"

vest financial

"25% vest on June 25, 2027 and the remainder vest quarterly"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

underlying security financial

"underlying_security_title: "Common Stock""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/29/2026 - 04:20 PM Accepted by SEC EDGAR 06/29/2026 - 04:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Heath-Chiozzi Margo

(Last) (First) (Middle)

C/O CELLDEX THERAPEUTICS, INC.

53 FRONTAGE ROAD, SUITE 220

(Street)

HAMPTON NEW JERSEY 08827

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Celldex Therapeutics, Inc. [ CLDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP OF REGULATORY AFFAIRS

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Stock Option (right to buy)(1)	$34.09	06/25/2026(1)		A		95,000		06/25/2027(2)	06/25/2036	Common Stock	95,000	$0	95,000	D

Explanation of Responses:

1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

2. 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

	/s/ Sam Martin, attorney-in-fact for Margo Heath-Chiozzi	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did the Celldex (CLDX) Form 4 filing report for Margo Heath-Chiozzi?

The filing shows SVP of Regulatory Affairs Margo Heath-Chiozzi received an incentive stock option grant for 95,000 shares. These options are part of her equity compensation and give her the right to buy Celldex common stock at a fixed exercise price.

How many Celldex (CLDX) stock options were granted and at what exercise price?

Margo Heath-Chiozzi was granted 95,000 incentive stock options, each with an exercise price of $34.09 per share. This price is the cost per share she must pay if she chooses to exercise the options in the future.

When do the new Celldex (CLDX) stock options for Margo Heath-Chiozzi vest?

Twenty-five percent of the options vest on June 25, 2027. The remaining 75% then vest in equal quarterly installments over the next 12 quarters, creating a multi-year vesting schedule tied to continued service with the company.

What is the expiration date of the Celldex (CLDX) stock options granted to Margo Heath-Chiozzi?

The incentive stock options expire on June 25, 2036. After that date, any unexercised options will lapse and can no longer be used to purchase Celldex common stock, limiting the time window to benefit from this award.

Under which plan were Margo Heath-Chiozzi’s Celldex (CLDX) options granted?

The options were granted under Celldex’s 2021 Omnibus Equity Incentive Plan. This plan governs how equity awards like stock options are issued to employees and executives as part of their long-term compensation structure.

How many Celldex (CLDX) options does Margo Heath-Chiozzi hold after this grant?

Following this transaction, Margo Heath-Chiozzi holds 95,000 incentive stock options directly. This reflects the full size of the new award reported in the Form 4, with no exercises or sales disclosed in this filing.